PF-04958242 + PF-04958242 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hearing Loss, Sensorineural
Conditions
Hearing Loss, Sensorineural
Trial Timeline
Dec 1, 2011 → Feb 1, 2013
NCT ID
NCT01518920About PF-04958242 + PF-04958242 + Placebo
PF-04958242 + PF-04958242 + Placebo is a phase 1 stage product being developed by Biogen for Hearing Loss, Sensorineural. The current trial status is completed. This product is registered under clinical trial identifier NCT01518920. Target conditions include Hearing Loss, Sensorineural.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01518920 | Phase 1 | Completed |
Competing Products
6 competing products in Hearing Loss, Sensorineural
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 41 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| PIPE-505 + Placebo | Contineum Therapeutics | Phase 1/2 | 33 |
| SENS-401 (R-Azasetron Besylate) | Sensorion | Phase 2 | 44 |
| SENS-401 + SENS-401 | Sensorion | Phase 2/3 | 57 |
| SENS-401 (R-Azasetron Besylate) | Sensorion | Phase 2 | 44 |